Non-disclosure of HIV status in UK sexual health clinics - A pilot study to identify non-disclosure within a national unlinked anonymous seroprevalence survey

Sexually Transmitted Infections

Volumn 89, Issue 2, 2013, Pages 120-121

  Sullivan, Ann Kathleen ^a   Savage, Emma J ^b   Lowndes, Catherine M ^b   Paul, George ^a   Murphy, Gary ^b   Carne, Simon ^b   Back, David J ^c   Gill, O Noel ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; TENOFOVIR;

ARTICLE; FEMALE; HEALTH CENTER; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT INFORMATION; PILOT STUDY; PRIORITY JOURNAL; SEROPREVALENCE; UNITED KINGDOM; VIRUS LOAD;

ANTI-HIV AGENTS; DISCLOSURE; GREAT BRITAIN; HIV INFECTIONS; HIV SEROPREVALENCE; HUMANS; MALE; PILOT PROJECTS; SERUM; VIRAL LOAD;

EID: 84874666799     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2012-050801     Document Type: Article

References (7)

1. Health Protection Agency. HIV in the United Kingdom; 2011 Report. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1317131685847 (accessed 20 Aug 2012).
2. Health Protection Agency. Unlinked Anonymous Survey of Genitourinary Clinic Attendees (GUM Anon Survey). http://www.hpa.org.uk/web/ HPAweb&HPAwebStandard/HPAweb-C/1202115 (accessed 20 Aug 2012).
3. Whitlock GG, Lowndes CM, Mercey DE, et al. Do HIV-infected individuals test for sexually transmitted infections at another sexual health clinic? Sex Transm Infect 2011; 87:253.
4. Grabar S, Selinger-Leneman H, Abgrall S, et al. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009; 23:1163-9.
5. Parry JV, Connell JA, Reinbott P, et al. GACPAT HIV 1 + 2: a simple, inexpensive assay to screen for, and discriminate between, anti-HIV 1 and anti-HIV 2. J Med Virol 1995; 45:10-16.
6. Else LJ. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:1455-65.
7. Else LJ, Jackson A, Puls R, et al. Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother 2012; 56:1427-33.